首页> 美国卫生研究院文献>Radiation Oncology (London England) >Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study
【2h】

Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study

机译:局部晚期肝细胞癌患者三维共形放射治疗/强度调节放射治疗与经导管动脉化疗栓塞联合治疗后索拉非尼的维持:I / II期研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThree-dimensional conformal radiation therapy (3DCRT)/intensity-modulated radiation therapy (IMRT) combined with or without transcatheter arterial chemoembolization (TACE) for locally advanced hepatocellular carcinoma (HCC) has shown favorable outcomes in local control and survival of locally advanced HCC. However, intra-hepatic spreading and metastasis are still the predominant treatment failure patterns. Sorafenib is a multikinase inhibitor with effects against tumor proliferation and angiogenesis. Maintenance Sorafenib would probably prevent or delay the intrahepatic and extrahepatic spread of HCC after radiotherapy, which provides the rationale for the combination of these treatment modalities.
机译:背景三维共形放射治疗(3DCRT)/强度调制放射治疗(IMRT)结合或不结合经导管动脉化疗栓塞(TACE)用于局部晚期肝细胞癌(HCC)已显示出在局部控制和局部晚期HCC生存中的良好结果。然而,肝内扩散和转移仍然是主要的治疗失败方式。索拉非尼是一种多激酶抑制剂,具有抗肿瘤增殖和血管生成的作用。维持索拉非尼可能会预防或延迟放疗后肝内和肝外肝癌的扩散,这为组合这些治疗方式提供了依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号